Novo Nordisk A/S

Novo Nordisk A/S is a leading global pharmaceutical company specializing in the development, manufacturing, and distribution of innovative medicines. Established in 1923 and headquartered in Bagsvaerd, Denmark, Novo Nordisk primarily focuses on diabetes and obesity care, with an extensive portfolio that includes insulin therapies, GLP-1 receptor agonists like Ozempic and Wegovy, and a range of smart delivery solutions such as insulin pens and digital dose guidance tools. Beyond its core diabetes and obesity segments, the company addresses rare diseases by offering treatments for rare blood and endocrine disorders, as well as hormone replacement therapies. Novo Nordisk plays a critical role in the healthcare sector, serving markets across Europe, North America, Asia, and the Middle East. Renowned for its research-driven approach and strategic collaborations—such as partnerships with organizations like UNICEF—the company is a key influencer in advancing global health, particularly in metabolic and chronic disease management. Its significant market capitalization and strong international presence underscore Novo Nordisk's importance in both the pharmaceutical industry and broader financial markets.